Fractyl Health Unveils a Game Changer in Metabolic Disease Treatment!

🚀 Breaking News from Fractyl Health! 🌟

Exciting developments in the battle against diabetes and obesity! Fractyl Health has announced groundbreaking results from its innovative Rejuva® platform. 🧬🔬

Key Points:

A single dose of human GLP-1 pancreatic gene therapy showed up to 50% blood sugar reduction and 11% weight loss in diabetic and obese mice.
These results surpassed those of chronic semaglutide, a current treatment, marking a significant advancement in metabolic disease therapy.
RJVA-001, the first clinical candidate from Rejuva®, showcases the potential of pancreatic GLP-1 for durable metabolic control. 🩺💊 This could be a game-changer in treating obesity and type 2 diabetes, aiming for lasting remission rather than just symptom management.

Fractyl Health is propelling forward with this innovative approach, with plans for human clinical trials set for the first half of 2025. Stay tuned for more on this revolutionary journey towards transforming metabolic disease treatment! 🌍💪

#FractylHealth #RejuvaPlatform #DiabetesResearch #ObesityTreatment #MetabolicHealth #InnovativeTherapy #HealthTech #BreakingScience